Results 141 to 150 of about 162,806 (305)

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

open access: yesHepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) is a common type of liver cancer. Recently, combination therapy with atezolizumab plus bevacizumab has become a standard systemic treatment for patients with unresectable HCC. Some HCCs show high signal intensity on the hepatobiliary phase of Gd‐EOB‐DTPA–enhanced MRI.
Tomoko Aoki   +24 more
wiley   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi   +8 more
wiley   +1 more source

Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

open access: yesHepatology Research, EarlyView.
In patients with cirrhosis and a first portal vein thrombosis treated with intravenous anticoagulant therapy, the 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively. A good radiological response was associated with fewer liver‐related hospitalizations.
Atsushi Maeda   +19 more
wiley   +1 more source

Short‐Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease

open access: yesHepatology Research, EarlyView.
Zinc deficiency is frequently seen in patients with chronic liver disease and is linked to poor appetite and nutritional status. We found that switching to zinc histidine hydrate increased zinc levels within a short period and was associated with improved appetite.
Yoshihito Uchida   +9 more
wiley   +1 more source

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development

open access: yesHepatology Research, EarlyView.
Patients with hepatocellular carcinoma (HCC) as well as chronic kidney disease (CKD) are high‐risk individuals, making it challenging to accurately predict their survival. We found that the PALBI grade model when combined with other patient's clinical and tumor‐related factors, forms a new and highly accurate prediction tool to estimate their ...
Jihye Lim   +2 more
wiley   +1 more source

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin

open access: yesHepatology Research, EarlyView.
The percentage of glycosylated ferritin relative to total ferritin (%GF) is a novel biomarker for hepatocellular carcinoma (HCC), showing diagnostic performance comparable to that of AFP and DCP. We developed the GFAD index by integrating age, sex, %GF, AFP, and DCP, achieving improved diagnostic accuracy with high sensitivity and specificity. ABSTRACT
Akiyo Ishiguro   +11 more
wiley   +1 more source

Duplication of the prothrombin gene is associated with a significant increase in thrombin generation. [PDF]

open access: yesRes Pract Thromb Haemost
Siegemund A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy